Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).

In the original publication, in Abstract, the sentence that reads as, "Oral S-1 at a dose of 80 mg/m was…………. drug-free interval" should read as, "Oral S-1 at a dose of 40 mg/m was administered twice daily for 2 weeks, followed by a 1-week drug-free interval.